Novo Nordisk recently announced the launch of a flexible subscription plan for its highly anticipated oral Wegovy, covering two dosage specifications: 9mg and 25mg.

Users can now choose from different subscription durations of 3 months, 6 months, or 12 months, and enjoy tiered pricing discounts: the 3-month package is priced at $289 per month, the 6-month package is reduced to $269 per month, while the 12-month long-term subscription offers an exceptional price of $249 per month. This subscription model aims to provide a more sustainable economic option for those with long-term weight management needs, while enhancing the continuity of medication use. As the oral version of Wegovy continues its penetration in the weight loss market, Novo Nordisk is further expanding its user base through diversified payment strategies.